Latest news with #QGEN
Yahoo
4 days ago
- Business
- Yahoo
QGEN Stock to Gain From Expanding Oncology Portfolio via New Alliances
QIAGEN N.V. QGEN announced the expansion of its oncology diagnostics portfolio with two strategic partnerships. The new collaborations with Tracer Biotechnologies and Foresight Diagnostics are set to advance the use of minimal residual disease (MRD) testing in clinical trials to support pharma co-development projects for companion diagnostics (CDx). MRD testing is becoming a cornerstone of oncology by enabling early detection of cancer recurrence and guiding timely adjustments to therapy from a blood sample. The latest partnerships support the growing demand for decentralized, non-invasive tools that advance precision medicine and help deliver more personalized care. Following the announcement yesterday, shares of QIAGEN ended the session at $44.90, down 0.5% from the previous close. On a promising note, the company's MRD portfolio spans sample technologies and testing platforms that support workflows from sample to insight. These new partnerships represent an important step in strengthening QIAGEN's leadership in oncology by aiming to bring innovative MRD technologies into clinical practice. The focus is on enhancing scalable, cost-effective solutions based on the QIAcuity digital PCR (dPCR) system, enabling laboratories and healthcare providers worldwide to use MRD insights for guiding personalized treatment decisions for cancer patients. As a result, we expect the developments to positively boost the market sentiment toward QGEN stock. QIAGEN has a market capitalization of $10.03 billion. The company's earnings yield of 5.2% compares favorably to the industry average of -32.1% yield. In the trailing four quarters, it delivered an average earnings surprise of 4.9%. Tracer Biotechnologies, a developer of blood-based molecular diagnostics for cancer, is working with QIAGEN to create CDx for MRD testing in solid tumors. These assays, intended for QIAGEN's QIAcuity dPCR platform, enable the use of minimally invasive blood samples to monitor residual disease with high sensitivity. The approach offers a cost-efficient and quick way to support decentralized implementation in clinical laboratories with results comparable to those generated using next-generation sequencing technologies. Image Source: Zacks Investment Research Foresight Diagnostics is a pioneering cancer diagnostics company focused on developing ultra-sensitive liquid biopsy tests for MRD detection. Together with QIAGEN, both are creating a kit-based version of the Foresight CLARITY assay — a circulating tumor DNA (ctDNA)-based NGS test for certain types of lymphoma. Transitioning the assay from a CLIA central laboratory service to an in-lab kit is designed to allow for broader clinical access and support pharmaceutical-sponsored trials with companion diagnostic applications. Per a research report, the global cancer diagnostics market was valued at $109.61 billion in 2024 and is expected to grow at a compound annual rate of 6.1% through 2030. The growing prevalence of cancer, technological advancements in diagnostics procedures and rising initiatives undertaken by private & public organizations are fueling the market's growth. Last month, QIAGEN announced a new commercial partnership and co-marketing agreement with ID Solutions — a French provider of high-quality dPCR assays and customized molecular testing solutions for oncology and other disease areas — to expand the availability of dPCR assays for oncology research applications. In the past six months, QGEN shares have dropped 0.3% compared with the industry's 11.7% decline. QIAGEN currently carries a Zacks Rank #2 (Buy). Some other top-ranked stocks in the broader medical space are Phibro Animal Health PAHC, Hims & Hers Health HIMS and Cencora COR. While Phibro Animal Health sports a Zacks Rank #1 (Strong Buy) at present, Hims & Hers Health and Cencora each carry a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here. Estimates for Phibro Animal Health's fiscal 2025 earnings per share have jumped 3.6% to $2.01 in the past 30 days. Shares of the company have rallied 36.2% in the past year compared with the industry's 10.5% growth. Its earnings yield of 8.7% compares comfortably with the industry's 0.5% yield. PAHC's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 30.6%. Hims & Hers Health shares have surged 176% in the past year. Estimates for the company's 2025 earnings per share have jumped 12.5% to 72 cents in the past 30 days. HIMS' earnings beat estimates twice in the trailing four quarters, matched in one and missed on another occasion, the average surprise being 19.6%. In the last reported quarter, it posted an earnings surprise of 66.7%. Estimates for Cencora's fiscal 2025 earnings per share have increased 2.5% to $15.75 in the past 30 days. Shares of the company have jumped 26.4% in the past year against the industry's 21% fall. COR's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6%. In the last reported quarter, it delivered an earnings surprise of 8.3%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report QIAGEN N.V. (QGEN) : Free Stock Analysis Report Cencora, Inc. (COR) : Free Stock Analysis Report Phibro Animal Health Corporation (PAHC) : Free Stock Analysis Report Hims & Hers Health, Inc. (HIMS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 days ago
- Business
- Yahoo
Why Qiagen (QGEN) is a Top Growth Stock for the Long-Term
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Many investors also have a go-to methodology that helps guide their buy and sell decisions. One way to find winning stocks based on your preferred way of investing is to use the Zacks Style Scores, which are indicators that rate stocks based on three widely-followed investing types: value, growth, and momentum. Different than value or momentum investors, growth-oriented investors are concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, they'll want to focus on the Growth Style Score, which analyzes characteristics like projected and historical earnings, sales, and cash flow to find stocks that will see sustainable growth over time. Based in Venlo, the Netherlands, QIAGEN N.V. is one of the world's leading providers of technologies and products for the separation, purification and handling of nucleic acids DNA/RNA. The company provides innovative technologies and products for pre-analytical sample preparation and molecular diagnostics solutions. It has developed a comprehensive portfolio of over 500 proprietary, consumable products, and automated solutions for sample collection. QGEN boasts a Growth Style Score of B and VGM Score of A, and holds a Zacks Rank #2 (Buy) rating. Its bottom-line is projected to rise 6.9% year-over-year for 2025, while Wall Street anticipates its top line to improve by 4%. Eight analysts revised their earnings estimate higher in the last 60 days for fiscal 2025, while the Zacks Consensus Estimate has increased $0.07 to $2.33 per share. QGEN also boasts an average earnings surprise of 4.9%. Qiagen is also cash rich. The company has generated cash flow growth of 3.3%, and is expected to report cash flow expansion of 0% in 2025. QGEN should be on investors' short lists because of its impressive growth fundamentals, a good Zacks Rank, and strong Growth and VGM Style Scores. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report QIAGEN N.V. (QGEN) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
23-05-2025
- Business
- Yahoo
QGEN Stock Might Gain Following New Partnership With ID Solutions
QIAGEN N.V. QGEN recently entered into a commercial partnership and co-marketing agreement with ID Solutions, a French provider of high-quality digital PCR (dPCR) assays, to expand the availability of dPCR assays for oncology research applications. The latest partnership is likely to expand QIAGEN's position in oncology-focused digital PCR assays, advancing QIAcuity as the platform of choice for cancer research. Following the announcement, shares of QIAGEN remained unchanged at $42.32 yesterday. QIAGEN's long-term business strategy involves entering into strategic alliances as well as making marketing and distribution arrangements with academic, corporate and other partners relating to the development, commercialization, marketing and distribution of certain of their existing and potential products. In line with this, QIAGEN's partnership with McGill University is aimed at enhancing its position in North America's $1.8 billion microbiome research market. Additionally, the company announced a collaboration with Eli Lilly and Company to support the development of a QIAstat-Dx in-vitro diagnostic (IVD) to detect APOE genotypes, which can play a key role in Alzheimer's disease diagnosis. As a result, we expect the new partnership with ID Solutions to positively boost the market sentiment toward QGEN stock. QIAGEN has a market capitalization of $9.16 billion. The company's earnings yield of 5.5% compares favorably to the industry's -33.5%. In the trailing four quarters, it delivered an average earnings surprise of 4.93%. Under the agreement, ID Solutions will manufacture and supply dPCR assays for non-clinical research use on QIAGEN's QIAcuity platforms. These assays are optimized to simultaneously detect multiple mutations in cell-free DNA (cfDNA) from plasma and genomic DNA (gDNA) from formalin-fixed, paraffin-embedded (FFPE) tissue. QIAGEN will commercialize these kits starting with Europe, with the potential for future expansion into other regions. The agreement supports QIAGEN's strategic focus on accelerating the adoption of the QIAcuity dPCR platform in oncology research. The new assays will expand QIAGEN's portfolio and complement the existing PanCancer Kits for detecting multiple hallmark mutations in DNA. The combination of QIAGEN's global reach and automation expertise with the assay development and manufacturing capabilities of ID Solutions will strengthen QIAGEN's position in oncology research. For customers, this partnership translates into streamlined access to ready-to-use assays optimized for QIAcuity in non-clinical oncology research, expanding beyond the current menu, enabling results in less than a day and meeting the growing demand for deeper molecular insights. Image Source: Zacks Investment Research Per the report from Research and Markets, the global digital PCR market was valued at $678.1 million in 2023 and is poised to reach $3.35 billion by 2034, marking a remarkable compound annual growth rate (CAGR) of 15.75% during 2024-2034. The market has been experiencing significant growth, primarily fueled by the rising adoption of personalized medicine to screen and diagnose genetic disorders. Additionally, the growing prevalence of infectious diseases is driving the demand for dPCR. Earlier this month, QIAGEN signed a definitive agreement to acquire Genoox, a provider of AI-powered software that enables clinical labs to scale and accelerate the processing of complex genetic tests. The acquisition adds Franklin — Genoox's flagship cloud-based community platform — to the QIAGEN Digital Insights ('QDI') portfolio. It further strengthens QIAGEN's leadership in genetic interpretation for clinical genomics applications. In the past year, QGEN's shares have lost 5.9% compared with the industry's 17.5% decline. The company currently carries a Zacks Rank #2 (Buy). Some other top-ranked stocks in the broader medical space are AngioDynamics ANGO, STERIS STE and DexCom DXCM. AngioDynamics, carrying a Zacks Rank #1 (Strong Buy) at present, has an estimated earnings growth rate of 23.7% for 2025. You can see the complete list of today's Zacks #1 Rank stocks here. ANGO's earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 70.85%. Veracyte's shares have risen 49.2% in the past year compared with the industry's 5.5% growth. STERIS, carrying a Zacks Rank #2 at present, has an estimated growth rate of 10.8% for 2025. STE's earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 0.61%. Its shares have risen 34.1% compared with the industry's 7.7% growth in the past year. DexCom, carrying a Zacks Rank #2 at present, has an estimated earnings growth rate of 23.2% for 2025. Its earnings surpassed estimates in two of the trailing four quarters and missed in the other two, delivering an average surprise of 0.47%. DXCM's shares have risen 26.4% against the industry's 15.7% decline in the past year. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AngioDynamics, Inc. (ANGO) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report QIAGEN N.V. (QGEN) : Free Stock Analysis Report STERIS plc (STE) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
13-05-2025
- Business
- Yahoo
QIAGEN Stock Gains Following the Acquisition of Genoox
QIAGEN N.V. QGEN recently signed a definitive agreement to acquire Genoox, a provider of AI-powered software that enables clinical labs to scale and accelerate the processing of complex genetic tests. The latest acquisition aims to bolster QIAGEN's next-generation sequencing (NGS) portfolio. Following the announcement, shares of the company moved north 2.3% to $42.96 yesterday. Over the past few quarters, the company has continuously integrated AI technology into the QDI portfolio. In 2024, QIAGEN introduced a new version of its clinical decision support software, QIAGEN Clinical Insight Interpret (QCI Interpret), to deliver significant performance and scalability enhancements for high-throughput, NGS labs transitioning to larger test panels and higher test volumes. The company also launched QCI Secondary Analysis — a cloud-based software-as-a-service (SaaS) solution that enables high-throughput secondary analysis for use with any clinical next-generation sequencing (NGS) data. Accordingly, we expect the latest acquisition of Genoox to bolster investor confidence and maintain an upward momentum in QGEN's share price in the upcoming days. QIAGEN currently has a market capitalization of $9.28 billion. The company delivered an average earnings surprise of 4.93% for the trailing four quarters. QIAGEN acquired Genoox for $70 million in cash, and is eligible for additional milestone payments of up to $10 million. The acquisition is expected to generate approximately $5 million in sales for QIAGEN in 2025 and have a neutral impact on adjusted earnings per share (EPS). The acquisition adds Franklin — Genoox's flagship cloud-based community platform — to the QIAGEN Digital Insights (QDI) portfolio. It further strengthens QIAGEN's leadership in genetic interpretation for clinical genomics applications. Franklin empowers labs to analyze next-generation sequencing (NGS) data from targeted gene panels to whole exome and genome sequencing (WES/WGS). It delivers real-time, AI-driven insights to support clinical decision-making. Franklin is currently used by over 4,000 healthcare organizations in more than 50 countries and has powered over 750,000 case interpretations to date. Image Source: Zacks Investment Research The acquisition paves the way to integrate QIAGEN's genomic content into the Franklin platform. This includes the Human Gene Mutation Database, the Catalogue of Somatic Mutations in Cancer and the QIAGEN Knowledge Base, all of which power the company's leading QCI Interpret and QCI Precision Insights solutions. Per a report by MarketsandMarkets, the global NGS market size was valued at $12.13 in 2023 and is expected to witness a compound annual growth rate (CAGR) of 13.2% from 2024 to 2029. The market is experiencing significant growth, driven by the rising demand for precision medicine and the confluence of technological advancements. The company expanded its cell and gene therapy (CGT) portfolio in the previous month with an enhanced digital PCR (dPCR) workflow that includes solutions for lentivirus-based applications, commonly used in the production of advanced treatments such as chimeric antigen receptor T-cell (CAR-T) therapies. In the past year, QGEN's shares have lost 8% compared with the industry's 21.4% decline. The company currently carries a Zacks Rank #2 (Buy). Some other top-ranked stocks in the broader medical space are AngioDynamics ANGO, STERIS STE and DexCom DXCM. AngioDynamics, carrying a Zacks Rank #1 (Strong Buy) at present, has an estimated earnings growth rate of 23.7% for 2025. You can see the complete list of today's Zacks #1 Rank stocks here. ANGO's earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 70.85%. Veracyte's shares have risen 49.2% in the past year compared with the industry's 5.5% growth. STERIS, carrying a Zacks Rank #2 (Buy) at present, has an estimated growth rate of 10.8% for 2025. STE's earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 0.61%. Its shares have risen 34.1% compared with the industry's 7.7% growth in the past year. DexCom, carrying a Zacks Rank #2 at present, has an estimated earnings growth rate of 23.2% for 2025. Its earnings surpassed estimates in two of the trailing four quarters and missed in the other two, delivering an average surprise of 0.47%. DXCM's shares have risen 26.4% against the industry's 15.7% decline in the past year. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AngioDynamics, Inc. (ANGO) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report QIAGEN N.V. (QGEN) : Free Stock Analysis Report STERIS plc (STE) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
03-05-2025
- Business
- Yahoo
Why Qiagen (QGEN) is a Top Value Stock for the Long-Term
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. While you may have an investing style you rely on, finding great stocks is made easier with the Zacks Style Scores. These are complementary indicators that rate stocks based on value, growth, and/or momentum characteristics. Different than growth or momentum investors, value-focused investors are all about finding good stocks at good prices, and discovering which companies are trading under what their true value is before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, and Price/Cash Flow to help pick out the most attractive and discounted stocks. Based in Venlo, the Netherlands, QIAGEN N.V. is one of the world's leading providers of technologies and products for the separation, purification and handling of nucleic acids DNA/RNA. The company provides innovative technologies and products for pre-analytical sample preparation and molecular diagnostics solutions. It has developed a comprehensive portfolio of over 500 proprietary, consumable products, and automated solutions for sample collection. QGEN boasts a Value Style Score of B and VGM Score of B, and holds a Zacks Rank #2 (Buy) rating. Shares of Qiagen are trading at a forward earnings multiple of 18.7X, as well as a PEG Ratio of 2.4, a Price/Cash Flow ratio of 13.3X, and a Price/Sales ratio of 4.8X. Many value investors pay close attention to a company's earnings as well. For QGEN, two analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.01 to $2.27 per share for 2025. Per share QGEN boasts an average earnings surprise of 3.6%. With strong valuation and earnings metrics, a good Zacks Rank, and top-tier Value and VGM Style Scores, investors should strongly think about adding QGEN to their portfolios. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report QIAGEN N.V. (QGEN) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
